The pooled HR for PFS was 1.30 (95% CI 0.91–1.86, p = 0.15), indicating a trend toward superiority of sunitinib over everolimus, although the results failed to reach statistical significance [ 113 ].
1
—
—
The pooled HR for PFS was 1.30 (95% CI 0.91–1.86, p = 0.15), indicating a trend toward superiority of sunitinib over everolimus, although the results failed to reach statistical significance [ 113 ].